SlideShare

SlideShare

Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort


Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. This study developed an eosinophil gradient algorithm using variables readily accessible in real-life and found that the eosinophilic severe asthma phenotype was more prevalent than previously thought. By shedding greater light on treatable traits, the delivery of precision medicine can be made more effective.

Potential Severe Asthma Hidden in UK Primary Care


Severe asthma patients often remain hidden in primary care, leading to suboptimal management of their disease and worsening of symptoms and an increase in overall burden. This study quantified the proportion of these “hidden” patients and described the common characteristics observed. Early identification of these patients and referral to specialist services is key in improving asthma outcomes, and characterizing this population may aid clinicians in recognizing severe asthma in primary care with greater precision.

BRISAR: Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry (ISAR)


As part of a larger endeavour to better characterize the international severe asthma population, this study looked to describe the differential expression of the various cellular pathways involved in the pathogenesis of this disease. Patients were evaluated by their levels of key biomarkers (pre-biologic initiation) and a high degree of overlap was observed. Furthermore, distinct patient clusters with associated clinical characteristics were identified. 

The findings of this study enable severe asthma phenotypes to be easily distinguished, which may aid in the delivery of precision medicine. Beyond that, it suggests that rather than relying on simple biomarker positivity, a more comprehensive approach – rather than relying on simple biomarker positivity – may be needed to identify the best therapy for patients.

ISAR: Protocol for a Global Registry


Due to the heterogeneity of the severe asthma population, severe asthma exerts a disproportionate burden on patients and healthcare worldwide. To aid in this endeavour, I
SAR aims to describe the protocol for registry development and management, the rationale behind each step, and the potential benefits of ISAR to the adult severe asthma population. 

ISAR: Mission Statement 


ISAR aims to improve the care of severe asthma patients by combining existing knowledge with new research. By examining real-world data on the efficacy and safety of different treatment options, we hope to make a positive impact on patient care. Check out our mission statement to learn more about what we hope to accomplish.